While G-CSF is commonly used after autologous HSCT and occasionally after allogeneic HSCT to minimize prolonged neutropenia and its associated morbidity and mortality [47,48,49], administration of G-CSF is not without risk [49,50]. This evidence concerns the gene CSF3 and neutropenia.